Targeted drug trial for tough prostate cancer cases shows promise
NCT ID NCT04631744
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tested the drug cabozantinib in men with a hard-to-treat type of prostate cancer that has spread and no longer responds to hormone therapy. The goal was to see if the drug could shrink tumors or slow the disease, especially in patients with certain gene changes or cancer in the liver. Only 4 men took part before the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.